Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported R&D Expense of $1.32 billion for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.32B | +17.2% |
| 2024 | $1.13B | +12.1% |
| 2023 | $1.00B | +13.7% |
| 2022 | $883.01M | +11.5% |
| 2021 | $792.16M | +21.0% |
| 2020 | $654.82M | -0.0% |
| 2019 | $655.11M | +29.6% |
| 2018 | $505.42M | +29.4% |
| 2017 | $390.63M | +2.2% |
| 2016 | $382.39M | +38.3% |
| 2015 | $276.50M | +45.3% |
| 2014 | $190.25M | +68.4% |
| 2013 | $112.96M | +30.5% |
| 2012 | $86.57M | -12.8% |
| 2011 | $99.30M | -6.7% |
| 2010 | $106.38M | -2.2% |
| 2009 | $108.73M | +12.2% |
| 2008 | $96.88M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $358.81M | +32.4% | +10.9% |
| June 30, 2025 | $323.62M | +10.0% | +22.1% |
| March 31, 2025 | $265.12M | +1.6% | -2.1% |
| September 30, 2024 | $270.93M | +7.0% | -7.9% |
| June 30, 2024 | $294.14M | +18.4% | +12.7% |
| March 31, 2024 | $261.00M | +13.2% | +3.1% |
| September 30, 2023 | $253.18M | +3.2% | +1.9% |
| June 30, 2023 | $248.53M | +20.8% | +7.8% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +17.2% in R&D Expense compared to the prior fiscal year.
- Over the 2008–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s r&d expense has grown by 1262.2% (from $96.88 million to $1.32 billion).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: